AbbVie Inc. (ABBV) Stock Analysis

Analysis from 10-Q filed 2026-08-03. Data as of Q2 2026.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 14.7%. FCF margin 28.3%. D/E -11.9x. Source: 10-Q filed 2026-08-03.

Metric	Value	Context
ROIC	14.7%	Solid returns
FCF Margin	28.3%	Strong cash generation
Debt/Equity	-11.9x	Conservative leverage

ROIC 14.7% — Top 25% of sector peers. FCF margin 28.3% — Top 5%.

Explore AbbVie Inc.: Earnings History | Filings

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for ABBV: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: AbbVie Inc. earns 14.7% ROIC, Top 25% in Healthcare

ROIC TTM 14.7%, sector median -7.5%, Top 25%. DuPont: NOPAT margin 19.0% × asset turnover 0.5x. Gross margin 71.5%. Operating margin 26.2%. Source: 10-Q filed 2026-08-03.

Metric	ABBV	Rating	Context
Return on Invested Capital (ROIC)	14.7%	Good	Above sector median of -7.5%
Return on Equity (ROE)	-161.5%	Red flag	Moderate equity returns
Gross Margin	71.5%	Excellent	Strong pricing power
Operating Margin	26.2%	Excellent	Efficient operations

---

Cash Flow: AbbVie Inc. generates $18.2B FCF at 28.3% margin, positive NaN/8 quarters

FCF TTM $18.2B. FCF margin 28.3%, Top 5%. OCF/Net income 3.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-08-03.

Metric	ABBV	Rating	Context
Free Cash Flow Margin	28.3%	Excellent	Excellent cash conversion
Free Cash Flow (TTM)	$18.2B	Good	Positive cash generation
OCF/Net Income	3.1x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet: AbbVie Inc. at -11.9x leverage, 5.8x interest coverage

Debt/Equity -11.9x. Total debt $70.8B, cash & investments $6.6B. Interest coverage 5.8x. Source: 10-Q filed 2026-08-03.

Metric	ABBV	Rating	Context
Debt to Equity	-11.9x	Excellent	Conservative capital structure
Net Cash Position	$-64.3B	Warning	Net debt position
Interest Coverage	5.8x	Good	Comfortable debt service

---

Valuation: AbbVie Inc. trades at 75.0x earnings

P/E 75.0x. EV/Sales 8.3x. FCF yield 3.9%. Dividend yield 2.6%. Source: 10-Q filed 2026-08-03.

Metric	ABBV	Rating	Context
P/E Ratio	75.0x	Warning	Premium valuation
EV/Sales	8.3x	Adequate	Growth premium priced in
FCF Yield	3.9%	Adequate	Lower cash yield
Dividend Yield	2.6%	Adequate	Growth focus over income

---

Capital Allocation: AbbVie Inc. returns 2.9% shareholder yield

Total shareholder yield 2.9% (div 2.6% + buyback 0.3%). Share count +0.0% YoY. Capital returned $13.5B TTM. Source: 10-Q filed 2026-08-03.

Metric	ABBV	Rating	Context
Total Shareholder Yield	2.9%	Adequate	Dividend + buyback yield combined
Buyback Yield	0.3%	Adequate	Minimal buyback activity
Share Count Change (YoY)	0.0%	Adequate	Net dilution from issuance/SBC
Total Capital Returned (TTM)	$13.5B	Good	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	14.7%	Top 25%	-
Free Cash Flow Margin	28.3%	Top 5%	-
Gross Margin	71.5%	Top 50%	1.1x above
Operating Margin	26.2%	Top 25%	-
Return on Equity (ROE)	-161.5%	Top 25%	-
P/E Ratio	75.0x	N/A	-

---

Financial Scorecard

Metric	ABBV	Rating	Sector Context
Return on Invested Capital (ROIC)	14.7%	Good	Top 25% of sector (median: -7.5%)
Free Cash Flow Margin	28.3%	Excellent	Top 5% of sector (median: 0.0%)
Gross Margin	71.5%	Excellent	Top 50% of sector (median: 63.8%)
Debt to Equity Ratio	-11.9x	Excellent	Conservative capital structure
P/E Ratio (Price-to-Earnings)	75.0x	Warning	High expectations priced in
Free Cash Flow Yield	3.9%	Adequate	Moderate yield

---

Frequently Asked Questions

Q: What is AbbVie Inc.'s Return on Invested Capital (ROIC)?

AbbVie Inc. (ABBV) has a trailing twelve-month Return on Invested Capital (ROIC) of 14.7%. The 8-quarter median ROIC is 13.0% with a improving trend. Sector median -7.5%. Source: 10-Q filed 2026-08-03.

Q: What is AbbVie Inc.'s Free Cash Flow Margin?

AbbVie Inc. (ABBV) has a free cash flow margin of 28.3%, generating $18.2 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-08-03.

Q: What is AbbVie Inc.'s P/E ratio and how does it compare to peers?

AbbVie Inc. (ABBV) trades at a P/E ratio of 75.0x, which is above the sector median of N/A. EV/Sales 8.3x. FCF yield 3.9%. Source: 10-Q filed 2026-08-03.

Q: Does AbbVie Inc. pay a dividend?

AbbVie Inc. (ABBV) currently pays a dividend yield of 2.6%. Total shareholder yield (dividend + buybacks) 2.9%. Source: 10-Q filed 2026-08-03.

Q: What is AbbVie Inc.'s revenue and earnings growth?

AbbVie Inc. (ABBV) grew revenue by 10.4% year-over-year. EPS +68.6% YoY. Source: 10-Q filed 2026-08-03.

Q: Is AbbVie Inc. buying back stock?

AbbVie Inc. (ABBV) repurchased $1.5 billion of stock over the trailing twelve months. This represents a buyback yield of 0.3%. Share count +0.0% YoY. Source: 10-Q filed 2026-08-03.

Q: How does AbbVie Inc. compare to competitors in Healthcare?

Compared to other companies in Healthcare, AbbVie Inc. (ABBV) shows: ROIC 14.7%, sector median -7.5% (Top 25%). FCF margin 28.3%, sector median 0.0% (Top 5%). Gross margin 71.5%, 7.6pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with AbbVie Inc.?

No quantitative warning flags fired for AbbVie Inc. (ABBV) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-08-03.

---

Data Source: Data sourced from 10-Q filed 2026-08-03. TTM metrics as of Q2 2026.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.